Advances in Therapy 2012; 29(12).
, Curtis BH, , . A UK Analysis of the Cost-Effectiveness of Humalog Mix75/25 and Mix50/50 Versus Long-Acting Basal Insulin.Roze S, Kurth H, Medical Devices: Evidence and Research 2012; 5: 97-101.
, , Marty R. Evaluation of the cost per patient per injection of botulinum toxin A in upper limb spasticity: comparison of two preparations in 19 countries.Blohmer JU, Rezai M, Kümmel S, Kühn T, Warm M, Friedrichs K, Benkow A, Journal of Medical Economics 2012.
, Eiermann W. Using the 21-gene assay to guide adjuvant chemotherapy decision-making in early-stage breast cancer: a cost-effectiveness evaluation in the German setting.Journal of Medical Economics 2012; 15(5): 977-86.
, Fajardo-Montañana C, , Ericsson A, . Long-term cost-effectiveness of insulin detemir versus NPH insulin in type 2 diabetes in Sweden.Journal of Medical Economics 2012; 15(4): 766-75.
, Curtis BH, . A long-term analysis evaluating the cost-effectiveness of biphasic insulin lispro mix 75/25 and mix 50/50 versus long-acting basal insulin analogs in the United States.Diabetic Medicine 2012; 29(3): 303-12.
, Jendle J, Saraheimo M, Thorsteinsson B, , Lammert M. Evaluating the cost-effectiveness of reduced mild hypoglycaemia in subjects with type 1 diabetes treated with Insulin detemir or NPH insulin in Denmark, Sweden, Finland and the Netherlands.Davies MJ, Chubb BD, Smith IC, Diabetic Medicine 2012; 29(3): 313-20.
. Cost-utility analysis of liraglutide compared with sulphonylurea or sitagliptin, all as add-on to metformin monotherapy in Type 2 diabetes mellitus.